Opko Health, Accuray, Medicines, DaVita, and DENTSPLY Intl. Early Briefing and Review

Mon Apr 15, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


LONDON,  April 15, 2013  /PRNewswire/ --

One of the most controversial features of the Affordable Care Act (ACA) has been
the 2.3% tax on total sales of taxable medical devices by medical equipment &
supplies companies. The controversial tax will lead to higher costs for medical
devices companies such as Accuray Incorporated (NASDAQ: ARAY) and DENTSPLY
International Inc. (NASDAQ: XRAY). On  March 21, however, the Senate voted 79 to
20 to pass a non-binding budget amendment, which encourages the repeal of the
medical device excise tax. The ACA is also expected to have a significant impact
on other players in the healthcare industry, including Opko Health Inc. (NYSE:
OPK), The Medicines Company (NASDAQ: MDCO), and DaVita Healthcare Partners Inc.
(NYSE: DVA). Healthcare stocks ended mostly lower on Friday, tracking losses in
the broad market, which struggled following the release of some disappointing
economic data. StockCall has released free charting and technical research on
these aforementioned companies. Register to read these reports at


Shares of Opko Health Inc. ended marginally lower in Friday's trading session.
The stock closed 0.28% lower at  $7.17  on volume of 807,625. Despite the
pullback last Friday, Opko's shares have gained more than 3.10% in the last
three sessions. The company's shares are currently trading close to their
52-week high of  $7.22. The stock has had an excellent run so far in 2013,
gaining more than 49%. Sign up for the free report on OPK at


Shares of Accuray Incorporated fluctuated between gains and losses on Friday
before finishing the day flat at  $4.81. Despite struggling for direction last
Friday, shares of ARAY have gained nearly 3.90% in the last three trading
sessions. The stock recently crossed above its 50-day moving average, which is a
bullish signal. The positive trend is further confirmed by its MACD chart. ARAY
free technical report can be accessed by signing up at


Shares of The Medicines Company's shares posted modest gains in Friday's
session. The stock closed 0.21% higher at  $32.82  on volume of 408,552. The
company shares have gained 3.40% in the last three trading sessions, which
indicates that market sentiment is currently bullish on the stock. It is
currently trading 6.73% below its 52-week high. Year-to-date, shares of MDCO
have gained nearly 37%, outperforming the S&P 500. Free report on MDCO can be
accessed by registering at


Shares of DaVita Healthcare Partners Inc. edged lower on Friday; however, the
losses were limited. The stock closed 0.11% lower at  $126.91  on volume of
447,300. The company's shares have outperformed the S&P 500 so far in 2013,
gaining more than 14.80%, compared to a gain of more than 11.40% for the S&P
500. DaVita's shares are currently trading well above its 50-day and 200-day
moving averages, which is a bullish signal. Register with StockCall and download
the research on DVA for free at


 Shares of DENTSPLY International Inc. edged lower in Friday's trading session.
The stock fell to an intra-day low of  $41.89  before paring some of the losses
to finish the day 0.43% lower at  $42.04  on above average volume of 680,800.
Despite the decline last Friday, DENTSPLY's shares have gained nearly 1.80% in
the last three sessions. The stock is currently struggling to break through 
$42.50  resistance level. It has support at around  $41.50. Read the full free
research on XRAY by signing up to StockCall at


About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up
today to talk to our financial analyst at


SOURCE  StockCall.com

Contact Person: William T. Knight, Email: info@stockcall.com, Contact Number:
+1(646)396-9857 (9:00 am EST - 01:30 pm EST)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.